Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
1(50.0%)
N/A
1(50.0%)
2Total
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06122987Phase 4Recruiting

Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

Role: lead

NCT04533360Completed

Prevalence of COVID-19 Antibodies Kingman AZ

Role: lead

NCT00623350Not ApplicableCompleted

Stroke DOC Arizona TIME - Stroke Team Remote Evaluation Using a Digital Observation Camera

Role: collaborator

All 3 trials loaded